Why might investors looking to get in on the next big biotech trend want to consider picking up shares of the company highlighted in today’s article? As the author explains, this company is “a novel drug discovery startup with a strong management team, access to one of the world’s most powerful supercomputers, and nearly $1 billion in funding, having completed the third-largest biotech IPO of all time in mid-July.” Moreover, shares of this early-stage biotech are currently available at a discount to their IPO price – but that may not last long. For more on this opportunity, CLICK HERE.